Roxadustat - Astellas Pharma/AstraZeneca/FibroGen

Drug Profile

Roxadustat - Astellas Pharma/AstraZeneca/FibroGen

Alternative Names: ASP 1517; AZD 9941; FG-4592

Latest Information Update: 05 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator FibroGen
  • Developer Astellas Pharma; AstraZeneca; FibroGen
  • Class Amides; Antianaemics; Carboxylic acids; Isoquinolines; Small molecules
  • Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Anaemia
  • Discontinued Sickle cell anaemia

Most Recent Events

  • 01 Oct 2018 Preregistration for Anaemia (associated with chronic kidney disease in patients on dialysis) in Japan (PO)
  • 15 Aug 2018 Astellas Pharma and FibroGen completes a phase III trial for Anaemia (in non-dialysis chronic kidney disease patients) in Japan (PO) (NCT02964936)
  • 06 Jul 2018 Astellas Pharma and Fibrogen completes a phase III trial for Anaemia in United Kingdom, Belgium, Bulgaria, Croatia, Czech Republic, France, Georgia, Germany, Hungary, Italy, Poland, Portugal, Romania, Russia, Spain, Slovakia and Serbia (PO) (NCT02278341) (EudraCT2013-001497-16)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top